Pieris Pharmaceuticals, Inc. announced on June 28, 2024, Les Laboratoires Servier and Institut de Recherches Internationales Servier (collectively, Servier), provided Pieris Pharmaceuticals, Inc. with a written notice of termination of the License and Collaboration Agreement between Servier, the company, and Pieris Pharmaceuticals GmbH, dated January 4, 2017, and subsequently amended (the Collaboration Agreement). Pursuant to Section 7.1 of the Non-Exclusive Anticalin® Platform Technology License Agreement, between Servier, the Company, and Pieris Pharmaceuticals GmbH, dated January 4, 2017 (the Non-Exclusive License Agreement), the Non-Exclusive License Agreement terminates upon termination of the Collaboration Agreement. The Collaboration Agreement and Non-Exclusive License Agreement (collectively, the Agreements) will terminate effective December 27, 2024, or 180 days from the date on which Servier notified the company of its intent to terminate the Agreements.

Pursuant to the Agreements, Servier and the Company agreed to collaborate on the research, development, and commercialization of Anticalin-based therapeutics as part of the company's immuno-oncology franchise, including S095012 (formerly, PRS-344), a 4-1BB/PD-L1 bispecific Mabcalin® protein that was being developed worldwide by Servier. With this notice, Servier will discontinue and cease dosing in the Phase 1 clinical study of S095012. Servier's decision to terminate the Agreements was based on a potential safety concern in the S095012 Phase 1 clinical studies.

The Company intends to review the safety data from the S095012 Phase 1 clinical study to understand the implications of the data. The Company does not intend to pursue any further development of S095012.